View Item 

Show simple item record

Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease

dc.contributor.authorDesai, Ami V.
dc.contributor.authorApplebaum, Mark A.
dc.contributor.authorKarrison, Theodore G.
dc.contributor.authorOppong, Akosua
dc.contributor.authorYuan, Cindy
dc.contributor.authorBerg, Katherine R.
dc.contributor.authorMacQuarrie, Kyle
dc.contributor.authorSokol, Elizabeth
dc.contributor.authorHall, Anurekha G.
dc.contributor.authorPinto, Navin
dc.contributor.authorWolfe, Ian
dc.contributor.authorMody, Rajen
dc.contributor.authorShusterman, Suzanne
dc.contributor.authorSmith, Valeria
dc.contributor.authorFoster, Jennifer H.
dc.contributor.authorNassin, Michele
dc.contributor.authorLaBelle, James L.
dc.contributor.authorBagatell, Rochelle
dc.contributor.authorCohn, Susan L.
dc.date.accessioned2022-08-02T18:58:22Z
dc.date.available2023-09-02 14:58:20en
dc.date.available2022-08-02T18:58:22Z
dc.date.issued2022-08-01
dc.identifier.citationDesai, Ami V.; Applebaum, Mark A.; Karrison, Theodore G.; Oppong, Akosua; Yuan, Cindy; Berg, Katherine R.; MacQuarrie, Kyle; Sokol, Elizabeth; Hall, Anurekha G.; Pinto, Navin; Wolfe, Ian; Mody, Rajen; Shusterman, Suzanne; Smith, Valeria; Foster, Jennifer H.; Nassin, Michele; LaBelle, James L.; Bagatell, Rochelle; Cohn, Susan L. (2022). "Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease." Cancer (15): 2967-2977.
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.urihttps://hdl.handle.net/2027.42/173128
dc.publisherWiley Periodicals, Inc.
dc.subject.otherautologous transplantation
dc.subject.othertreatment response
dc.subject.othersurvival
dc.subject.otherprognosis
dc.subject.otherneuroblastoma
dc.titleEfficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/173128/1/cncr34263-sup-0003-TableS1.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/173128/2/cncr34263_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/173128/3/cncr34263-sup-0001-FigS1.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/173128/4/cncr34263.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/173128/5/cncr34263-sup-0002-FigS2.pdf
dc.identifier.doi10.1002/cncr.34263
dc.identifier.sourceCancer
dc.identifier.citedreferencePark JR, Bagatell R, Cohn SL, et al. Revisions to the International Neuroblastoma Response Criteria: a consensus statement from the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2017; 35: 2580 - 2587.
dc.identifier.citedreferencePinto NR, Applebaum MA, Volchenboum SL, et al. Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol. 2015; 33: 3008 - 3017.
dc.identifier.citedreferenceBagatell R, Cohn SL. Genetic discoveries and treatment advances in neuroblastoma. Curr Opin Pediatr. 2016; 28: 19 - 25.
dc.identifier.citedreferenceLiang WH, Federico SM, London WB, et al. Tailoring therapy for children with neuroblastoma on the basis of risk group classification: past, present, and future. JCO Clin Cancer Inform. 2020; 4: 895 - 905.
dc.identifier.citedreferenceIrwin MS, Park JR. Neuroblastoma: paradigm for precision medicine. Pediatr Clin North Am. 2015; 62: 225 - 256.
dc.identifier.citedreferenceLadenstein R, Potschger U, Pearson ADJ, et al. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. Lancet Oncol. 2017; 18: 500 - 514.
dc.identifier.citedreferencePark JR, Kreissman SG, London WB, et al. Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: a randomized clinical trial. JAMA. 2019; 322: 746 - 755.
dc.identifier.citedreferenceLondon WB, Bagatell R, Weigel BJ, et al. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children’s Oncology Group early-phase trials. Cancer. 2017; 123: 4914 - 4923.
dc.identifier.citedreferenceLondon WB, Castel V, Monclair T, et al. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol. 2011; 29: 3286 - 3292.
dc.identifier.citedreferenceMoreno L, Rubie H, Varo A, et al. Outcome of children with relapsed or refractory neuroblastoma: a meta-analysis of ITCC/SIOPEN European phase II clinical trials. Pediatr Blood Cancer. 2017; 64: 25 - 31.
dc.identifier.citedreferenceZhou MJ, Doral MY, DuBois SG, Villablanca JG, Yanik GA, Matthay KK. Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG). Eur J Cancer. 2015; 51: 2465 - 2472.
dc.identifier.citedreferencePinto N, Naranjo A, Hibbitts E, et al. Predictors of differential response to induction therapy in high-risk neuroblastoma: a report from the Children’s Oncology Group (COG). Eur J Cancer. 2019; 112: 66 - 79.
dc.identifier.citedreferenceYanik GA, Parisi MT, Shulkin BL, et al. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children’s Oncology Group. J Nucl Med. 2013; 54: 541 - 548.
dc.identifier.citedreferenceLadenstein R, Lambert B, Potschger U, et al. Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials. Eur J Nucl Med Mol Imaging. 2018; 45: 292 - 305.
dc.identifier.citedreferenceMody R, Naranjo A, Van Ryn C, et al. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Lancet Oncol. 2017; 18: 946 - 957.
dc.identifier.citedreferenceMody R, Yu AL, Naranjo A, et al. Irinotecan, temozolomide, and dinutuximab with GM-CSF in children with refractory or relapsed neuroblastoma: a report from the Children’s Oncology Group. J Clin Oncol. 2020; 38: 2160 - 2169.
dc.identifier.citedreferenceDuBois SG, Matthay KK. 131I-metaiodobenzylguanidine therapy in children with advanced neuroblastoma. Q J Nucl Med Mol Imaging. 2013; 57: 53 - 65.
dc.identifier.citedreferenceLondon WB, Frantz CN, Campbell LA, et al. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children’s Oncology Group study. J Clin Oncol. 2010; 28: 3808 - 3815.
dc.identifier.citedreferenceBagatell R, London WB, Wagner LM, et al. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children’s Oncology Group study. J Clin Oncol. 2011; 29: 208 - 213.
dc.identifier.citedreferenceMaris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007; 369: 2106 - 2120.
dc.identifier.citedreferenceSharp SE, Gelfand MJ, Shulkin BL. Pediatrics: diagnosis of neuroblastoma. Semin Nucl Med. 2011; 41: 345 - 353.
dc.identifier.citedreferenceKaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457 - 481.
dc.identifier.citedreferencePeto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc Series A Gen. 1972; 135: 185 - 207.
dc.identifier.citedreferenceLondon WB, Castleberry RP, Matthay KK, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children’s Oncology Group. J Clin Oncol. 2005; 23: 6459 - 6465.
dc.identifier.citedreferenceCohn SL, Tweddle DA. MYCN amplification remains prognostically strong 20 years after its “clinical debut”. Eur J Cancer. 2004; 40: 2639 - 2642.
dc.identifier.citedreferenceDuBois SG, Granger MM, Groshen S, et al. Randomized phase II trial of MIBG versus MIBG, vincristine, and irinotecan versus MIBG and vorinostat for patients with relapsed or refractory neuroblastoma: a report from NANT consortium. J Clin Oncol. 2021; 39: 3506 - 3514.
dc.identifier.citedreferenceDuBois SG, Marachelian A, Fox E, et al. Phase I study of the aurora A kinase inhibitor alisertib in combination with irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma: a NANT (New Approaches to Neuroblastoma Therapy) trial. J Clin Oncol. 2016; 34: 1368 - 1375.
dc.identifier.citedreferencevon Allmen D, Davidoff AM, London WB, et al. Impact of extent of resection on local control and survival in patients from the COG A3973 study with high-risk neuroblastoma. J Clin Oncol. 2017; 35: 208 - 216.
dc.identifier.citedreferenceSimon T, Haberle B, Hero B, von Schweinitz D, Berthold F. Role of surgery in the treatment of patients with stage 4 neuroblastoma age 18 months or older at diagnosis. J Clin Oncol. 2013; 31: 752 - 758.
dc.identifier.citedreferenceHolmes K, Potschger U, Pearson ADJ, et al. Influence of surgical excision on the survival of patients with stage 4 high-risk neuroblastoma: a report from the HR-NBL1/SIOPEN study. J Clin Oncol. 2020; 38: 2902 - 2915.
dc.identifier.citedreferenceRyan AL, Akinkuotu A, Pierro A, Morgenstern DA, Irwin MS. The role of surgery in high-risk neuroblastoma. J Pediatr Hematol Oncol. 2020; 42: 1 - 7.
dc.identifier.citedreferenceMora J, Castaneda A, Gorostegui M, et al. Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission. Pediatr Blood Cancer. 2021; 68: e29121.
dc.identifier.citedreferenceHaghiri S, Fayech C, Mansouri I, et al. Long-term follow-up of high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell transplantation rescue. Bone Marrow Transplant. 2021; 56: 1984 - 1997.
dc.identifier.citedreferenceJodele S, Dandoy CE, Myers K, et al. High-dose carboplatin/etoposide/melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma. Bone Marrow Transplant. 2018; 53: 1311 - 1318.
dc.identifier.citedreferenceGaraventa A, Luksch R, Biasotti S, et al. A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma. Cancer. 2003; 98: 2488 - 2494.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr34263-sup-0003-TableS1.pdf
Size:
49.12KB
Format:
PDF
View/Open
Name:
cncr34263_am.pdf
Size:
390.8KB
Format:
PDF
View/Open
Name:
cncr34263-sup-0001-FigS1.pdf
Size:
60.54KB
Format:
PDF
View/Open
Name:
cncr34263.pdf
Size:
718.3KB
Format:
PDF
View/Open
Name:
cncr34263-sup-0002-FigS2.pdf
Size:
83.42KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.